These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 34287110)

  • 1. Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence among laboratory staff: Safe handling of coronavirus disease 2019 (COVID-19) samples.
    Hartard C; Agrinier N; Franck P; Prin-Mathieu C; Debourgogne A; Venard V; Schvoerer E; Jeulin H
    Infect Control Hosp Epidemiol; 2022 Nov; 43(11):1738-1740. PubMed ID: 34287110
    [No Abstract]   [Full Text] [Related]  

  • 2. Seroprevalence of SARS-CoV-2-Specific Antibodies, Faroe Islands.
    Petersen MS; Strøm M; Christiansen DH; Fjallsbak JP; Eliasen EH; Johansen M; Veyhe AS; Kristiansen MF; Gaini S; Møller LF; Steig B; Weihe P
    Emerg Infect Dis; 2020 Nov; 26(11):2761-2763. PubMed ID: 32726200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trend in Sensitivity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Serology One Year After Mild and Asymptomatic Coronavirus Disease 2019 (COVID-19): Unpacking Potential Bias in Seroprevalence Studies.
    Bailie CR; Tseng YY; Carolan L; Kirk MD; Nicholson S; Fox A; Sullivan SG
    Clin Infect Dis; 2022 Aug; 75(1):e357-e360. PubMed ID: 35026841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are Seroprevalence Estimates for Severe Acute Respiratory Syndrome Coronavirus 2 Biased?
    Takahashi S; Greenhouse B; Rodríguez-Barraquer I
    J Infect Dis; 2020 Nov; 222(11):1772-1775. PubMed ID: 32856712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Estimated Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Through Commercial Laboratory Residual Sera Testing and a Community Survey.
    Bajema KL; Dahlgren FS; Lim TW; Bestul N; Biggs HM; Tate JE; Owusu C; Szablewski CM; Drenzek C; Drobeniuc J; Semenova V; Li H; Browning P; Desai R; Epperson M; Jia LT; Thornburg NJ; Edens C; Fry AM; Hall AJ; Schiffer J; Havers FP
    Clin Infect Dis; 2021 Nov; 73(9):e3120-e3123. PubMed ID: 33300579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2-Specific Antibodies in Domestic Cats during First COVID-19 Wave, Europe.
    Schulz C; Martina B; Mirolo M; Müller E; Klein R; Volk H; Egberink H; Gonzalez-Hernandez M; Kaiser F; von Köckritz-Blickwede M; Osterhaus A
    Emerg Infect Dis; 2021 Dec; 27(12):3115-3118. PubMed ID: 34695368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020.
    Shakiba M; Nazemipour M; Salari A; Mehrabian F; Nazari SSH; Rezvani SM; Ghasempour Z; Heidarzadeh A; Mansournia MA
    Emerg Infect Dis; 2021 Feb; 27(2):636-638. PubMed ID: 33349310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seroprevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) antibodies among healthcare workers with differing levels of coronavirus disease 2019 (COVID-19) patient exposure.
    Hunter BR; Dbeibo L; Weaver CS; Beeler C; Saysana M; Zimmerman MK; Weaver L
    Infect Control Hosp Epidemiol; 2020 Dec; 41(12):1441-1442. PubMed ID: 32741406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seroprevalence of SARS-CoV-2 and Infection Fatality Ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020.
    Feehan AK; Fort D; Garcia-Diaz J; Price-Haywood EG; Velasco C; Sapp E; Pevey D; Seoane L
    Emerg Infect Dis; 2020 Nov; 26(11):2766-2769. PubMed ID: 32731911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seroprevalence of antibodies against severe acute respiratory coronavirus 2 (SARS-CoV-2) in household dogs in Japan.
    Ito G; Goto-Koshino Y; Kuroda Y; Eunsil P; Maeda K; Soma T; Momoi Y
    J Vet Med Sci; 2021 Nov; 83(11):1722-1725. PubMed ID: 34556605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seroprevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) antibodies by risk of exposure in a community health system.
    Fletcher JJ; Feucht EC; Hahn PY; McGoff TN; Dehart DJ; Mortada MEE; Grifka RG
    Infect Control Hosp Epidemiol; 2022 Mar; 43(3):407-409. PubMed ID: 33427131
    [No Abstract]   [Full Text] [Related]  

  • 12. Rapid Increase of Community SARS-CoV-2 Seroprevalence during Second Wave of COVID-19, Yaoundé, Cameroon.
    Ndongo FA; Guichet E; Mimbé ED; Ndié J; Pelloquin R; Varloteaux M; Esemu L; Mpoudi-Etame M; Lamare N; Edoul G; Wouambo RK; Djomsi DM; Tongo M; Tabala FN; Dongmo RK; Diallo MSK; Bouillin J; Thaurignac G; Ayouba A; Peeters M; Delaporte E; Bissek AZ; Mpoudi-Ngolé E
    Emerg Infect Dis; 2022 Jun; 28(6):1233-1236. PubMed ID: 35470795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unrecognized severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence among healthcare personnel in a low-prevalence area.
    Shah VP; Hainy CM; Swift MD; Breeher LE; Theel ES; Sampathkumar P
    Infect Control Hosp Epidemiol; 2021 Dec; 42(12):1532-1534. PubMed ID: 33213552
    [No Abstract]   [Full Text] [Related]  

  • 14. Low Seroprevalence among Undetected COVID-19 Cases, Faroe Islands, November 2020.
    Petersen MS; Strøm M; Fjallsbak JP; Hansen JL; Larsen S; Eliasen EH; Johansen M; Veyhe AS; Kristiansen MF; Weihe P
    Emerg Infect Dis; 2022 Jan; 28(1):242-244. PubMed ID: 34757895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-Vaccination Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in Workers at Three Japanese Hospitals.
    Takayama Y; Komatsu T; Wada T; Nihonyanagi S; Hoshiyama T; Moriya T; Shimamura S; Kajigaya N; Naito M; Takeuchi O; Bando Y; Watanabe M; Iwamura M; Hanaki H
    J Nippon Med Sch; 2022 Nov; 89(5):513-519. PubMed ID: 35644553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence among healthcare workers in a low prevalence region.
    Godbout EJ; Pryor R; Harmon M; Montpetit A; Greer J; Bachmann LM; Doll M; Stevens MP; Bearman G
    Infect Control Hosp Epidemiol; 2022 Jan; 43(1):120-122. PubMed ID: 33308349
    [No Abstract]   [Full Text] [Related]  

  • 17. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in the staff of a public school system in the midwestern United States.
    Lopez L; Nguyen T; Weber G; Kleimola K; Bereda M; Liu Y; Accorsi EK; Skates SJ; Santa Maria JP; Smith KR; Kalinich M
    PLoS One; 2021; 16(6):e0243676. PubMed ID: 34111144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 Period Seroprevalence and Related Factors, Hillsborough County, Florida, USA, October 2020-March 2021.
    Giuliano AR; Pilon-Thomas S; Schell MJ; Abrahamsen M; Islam JY; Isaacs-Soriano K; Kennedy K; Dukes CW; Whiting J; Rathwell J; Hensel JA; Mangual LN; Schonbrunn E; Bikowitz M; Grassie D; Yang Y
    Emerg Infect Dis; 2022 Mar; 28(3):556-563. PubMed ID: 35081021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 Seroprevalence in Children from Western Romania, March to June 2021.
    Olariu TR; Craciun AC; Vlad DC; Dumitrascu V; Pop LL; Horhat F; Lupu MA
    Vector Borne Zoonotic Dis; 2022 Apr; 22(4):267-270. PubMed ID: 35384727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 Seroprevalence before Delta Variant Surge, Chattogram, Bangladesh, March-June 2021.
    Bhuiyan TR; Hulse JD; Hegde ST; Akhtar M; Islam T; Khan ZH; Khan II; Ahmed S; Rashid M; Rashid R; Gurley ES; Shirin T; Khan AI; Azman AS; Qadri F
    Emerg Infect Dis; 2022 Feb; 28(2):429-431. PubMed ID: 35076007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.